Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212421 | 0.94 | HRH3 (0.51) | HRH3ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL8212505 | 0.84 | HRH3 (0.56) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8218300 | 0.82 | HRH3 (0.54) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8216741 | 0.79 | HRH3 (0.51) | HRH3ALDH1A1KDM4EKDRSMN1; SMN2 | |
| SCHEMBL16356942 | 0.78 | HRH3 (0.60) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8208530 | 0.78 | HRH3 (0.60) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8215808 | 0.76 | HRH3 (0.55) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8208836 | 0.76 | MEN1 (0.52) | ALDH1A1MAPTSMN1; SMN2LMNAFAAH | |
| SCHEMBL8216193 | 0.76 | HRH3 (0.57) | HRH3ALDH1A1MAPTKDM4EKDR | |
| SCHEMBL8215635 | 0.74 | NPC1 (0.61) | ALDH1A1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064732-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | HRH3 2338/4885ALDH1A1 1502/4885MAPT 739/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | HRH3 2524/4885ALDH1A1 1369/4885MAPT 874/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | HRH3 2975/4885ALDH1A1 1607/4885MAPT 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.